Jade Biosciences (JBIO) Convertible Debt (2024)
Jade Biosciences' (JBIO) quarterly Convertible Debt came in at $107.6 million in Q4 2024.
Jade Biosciences (JBIO) Convertible Debt (2024) Analysis & Trends
Jade Biosciences (JBIO) has 1 years of Convertible Debt data on file, last reported at $107.6 million in Q4 2024.
- Quarterly Convertible Debt changed N/A year-over-year to $107.6 million in Q4 2024, while the trailing twelve-month figure through Dec 2024 was $107.6 million (changed N/A YoY) and the FY2024 annual result came in at $107.6 million, changed N/A from the prior year.
- Convertible Debt steadied at $107.6 million in Q4 2024.
- In the past five years, Convertible Debt ranged from a high of $107.6 million in Q4 2024 to a low of $107.6 million in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Jade Biosciences | 1.57 Bn | 1.11 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 107.60 Mn |